Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results
Date:11/2/2011

NEW YORK, Nov. 2, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease (the "Company"), today announced its results for the third quarter ended September 30, 2011.

At September 30, 2011, the Company had cash, cash equivalents, interest receivable and investment securities of $47.2 million.  During the third quarter ended September 30, 2011, the Company received approximately $1.8 million in proceeds from the exercise of stock options.

The net loss for the third quarter ended September 30, 2011 was $10.2 million, or $0.15 per share, compared to a net loss of $5.8 million, or $0.10 per share, for the third quarter in 2010, representing an increase in net loss of $4.4 million.  Other research and development expenses for the third quarter ended September 30, 2011, increased by $4.7 million, as compared to the third quarter of 2010, principally related to the KRX-0401 (perifosine) and Zerenex Phase 3 clinical programs.  The net loss for the third quarter ended September 30, 2011, included $0.5 million of non-cash compensation expense related to equity incentive grants.

The net loss for the nine months ended September 30, 2011 was $19.7 million, or $0.30 per share, compared to a net loss of $15.0 million, or $0.26 per share, for the comparable period in 2010, representing an increase in net loss of $4.7 million.  The nine months ended September 30, 2011 included license revenue of $5.0 million related to a milestone payment from the Company's Japanese partner for Zerenex (ferric citrate), Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd., for their commencement of a Phase 3 clinical program of ferric citrate in Japan. Other research and development expenses for the nine months ended September 30, 2011, increased by $9.9 million, as compared to the comparable period in 2010, principally related to the KRX-0401 (perifosine) and Zerenex Phase 3 clinical programs.  The net loss for the nine months ended September 30, 2011, included $1.6 million of non-cash compensation expense related to equity incentive grants.

Commenting on the quarter, Ron Bentsur, the Company's Chief Executive Officer, said, "During the third quarter, we continued to move our Phase 3 programs forward, including the completion of patient enrollment into our Phase 3 studies for Perifosine in metastatic colorectal cancer and Zerenex in hyperphosphatemia.  We eagerly await the data from our Phase 3 studies in 2012."  Mr. Bentsur continued, "Our financial position remains strong and we are well capitalized to continue to execute on our business plan."  

The Company will host an investor conference call tomorrow, Thursday, November 3, 2011, at 8:30am EDT, to discuss the Company's third quarter financial results and provide a business outlook for the remainder of 2011.

In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

ABOUT KERYX BIOPHARMACEUTICALS, INC.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA.  Keryx is headquartered in New York City.

Cautionary StatementSome of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially are identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

KERYX CONTACT:
Lauren Fischer
Director – Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com Keryx Biopharmaceuticals, Inc.Selected Consolidated Financial Data(In Thousands, Except Share and Per Share Amounts)Statements of Operations Information (Unaudited):Three Months Ended

September 30,Nine Months Ended
September 30,2011201020112010REVENUE:License revenue

$
--

$
--

$
5,000

$
--OPERATING EXPENSES:Research and development:Non-cash compensation

152

322

616

998Other research and development

8,620

3,901

19,533

9,584Total research and development

8,772

4,223

20,149

10,582General and administrative:Non-cash compensation

320

291

948

959Other general and administrative

1,263

1,419

3,951

3,673Total general and administrative

1,583

1,710

4,899

4,632TOTAL OPERATING EXPENSES10,355

5,933

25,048

15,214OPERATING LOSS(10,355)

(5,933)

(20,048)

(15,214)OTHER INCOME:Interest and other income, net

108

85

300

197NET LOSS$  (10,247)

$  (5,848)

$
(19,748)

$   (15,017)NET LOSS PER COMMON SHAREBasic and diluted net loss per common share

$
(0.15)

$
(0.10)

$
(0.30)

$
(0.26)SHARES USED IN COMPUTING NET LOSS

PER COMMON SHAREBasic and diluted

70,483,909

59,324,661

66,139,443

58,219,823Balance Sheet Information:September 30, 2011(unaudited)December 31, 2010*Cash, cash equivalents, interest receivableand short-term investment securities

$
47,161$
28,512Total assets

51,45432,114Accumulated deficit

(361,512)(341,764)Stockholders' equity

38,89423,248* Condensed from audited financial statements.
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2011 Financial Results
2. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
3. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2011 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
5. Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering
6. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
7. Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
8. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
10. Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundations 2011 Spring Clinical Meetings
11. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... SAN DIEGO , Feb. 10, 2016 ... viral gene therapy manufacturing, and Renova™ Therapeutics, a biopharmaceutical ... and other chronic diseases, have entered into a Manufacturing ... produce cGMP-grade RT-100 (Ad5.hAC6) Drug Product for use in ... --> This relationship will leverage Lonza,s ...
(Date:2/10/2016)... Calif. , Feb. 10, 2016  Rich Pharmaceuticals, ... today announced a 1-for-100 reverse split of its issued ... opening of trading on Thursday, February 11, 2016. The ... under new CUSIP number 76303T308 and temporary ticker symbol ... commence trading under the ticker symbol (RCHA).  ...
(Date:2/10/2016)... , Feb. 10, 2016  The ALS Association, in partnership ... Grand Challenge to generate a biomarker to track TDP43 aggregation. ... up to a $1 million investment. ... disease that affects nerve cells in the brain and the ... initiate and control muscle movement, which often leads to total ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Ongoing news of the ... Care Association™ (ALCA) to conduct a survey that takes a closer look at cases ... illustrates the prevalence and causes of TBI among the aging population, and identifies the ...
(Date:2/10/2016)... ... 10, 2016 , ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company ... and full year ended December 31, 2015 on Monday, February 29, 2016 after the ... investment community following the release at 4:30 PM ET. Investors interested in participating by ...
(Date:2/10/2016)... ... 2016 , ... For additional information contact Phyllis Strupp 480-488-5858 , Brain improves ... The Ultimate Guide to Brain Training" by award-winning author Phyllis Strupp explains ... is March 16, 2016. A free review copy is available to the media ...
(Date:2/10/2016)... ... February 10, 2016 , ... IDEX Health & Science, LLC ... steel (PLS) columns combine the strength of traditional stainless steel with the chemical ... samples while operating at ultra-high pressures of 20,000 psi. The higher operating pressures ...
(Date:2/10/2016)... , ... February 10, 2016 , ... The recreational use ... enthusiasts in the state still face a lot of restrictions as to where they ... intended for private, personal use” and that cannabis “may not be consumed openly or ...
Breaking Medicine News(10 mins):